RE:RE:RE:LabelThat link referred to mitomycin C...not the same thing that what you wrote in your first post (minoclycin....an antiobiotic) !
Mitomycin C was the comparator in what was supposed to be the second phase 3 for MCNA. The recurrence-free survival (RFS) numbers cited are not that much impressive for papillary-only tumors. The difference with the BCG group (the comparator) was non-significant. Also note that this study group did not include high-risk NMIBC patients that previoulsy failed BCG treatment. You can't compare these numbers with the ones from study 301.
I can assure you that once approved, MCNA won't "lose" a lot of patients to mitomycin C.
M80